Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

Brufsky, Adam; Harker, W Graydon; Beck, J Thaddeus; Carroll, Robert; Tan-Chiu, Elizabeth; Seidler, Christopher; Hohneker, John; Lacerna, Leo; Petrone, Stephanie; Perez, Edith A

Brufsky, Adam; Harker, W Graydon; Beck, J Thaddeus; Carroll, Robert; Tan-Chiu, Elizabeth; Seidler, Christopher; Hohneker, John; Lacerna, Leo; Petrone, Stephanie; Perez, Edith A.

Affiliation

Brufsky A; Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15123, USA. brufskyam@upmc.edu

J Clin Oncol ; 25(7): 829-36, 2007 Mar 01.

Article in En | MEDLINE | ID: mdl-17159193

Subject(s)

Breast Neoplasms/drug therapy; Diphosphonates/therapeutic use; Imidazoles/therapeutic use; Nitriles/adverse effects; Osteoporosis, Postmenopausal/prevention & control; Triazoles/adverse effects; Adult; Aged; Alkaline Phosphatase/blood; Bone Density/drug effects; Collagen Type I/blood; Diphosphonates/adverse effects; Female; Humans; Imidazoles/adverse effects; Letrozole; Middle Aged; Peptides/blood; Zoledronic Acid

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Breast Neoplasms / Osteoporosis, Postmenopausal / Diphosphonates / Imidazoles / Nitriles Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2007 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links